ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

28 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

08 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

15 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology

02 Jun 2022 16:10:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

26 May 2022 08:00:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

04 May 2022 16:05:03 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

02 May 2022 16:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

05 Apr 2022 16:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

09 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference

02 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

18 Feb 2022 11:35:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

15 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

02 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022

24 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition

10 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

29 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

13 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

02 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients

11 Nov 2021 17:52:49 By Nasdaq GlobeNewswire